Drug intelligence / Profile preview

yupingfeng

Development stage
Phase 2
Modality
Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
Administration
Oral
01

Overview

Yupingfeng is a traditional Chinese medicine (TCM) herbal formula composed of three main ingredients: Astragali Radix (Huangqi), Atractylodis Macrocephalae Rhizoma (Baizhu), and Saposhnikoviae Radix (Fangfeng)[7]. It is widely used in TCM for its purported ability to "tonify Qi," strengthen the body's exterior defenses against pathogens, and regulate immune function[1][2][7]. Mechanistically, preclinical and clinical studies suggest that Yupingfeng exerts immunomodulatory effects by enhancing both innate and adaptive immunity. It has been shown to modulate cytokine production (such as reducing IL-5 and IL-13 in asthma models), restore epithelial barrier integrity via upregulation of desmoglein 1 in bronchial tissue[2], reduce serum IgE levels[3][7], decrease oxidative stress markers such as MDA[3], and improve microecological balance in chronic respiratory diseases[5]. Clinically it is most commonly used for recurrent respiratory tract infections (RRTIs) in children[1][8], allergic rhinitis[4][6][7], chronic obstructive pulmonary disease (COPD)[5], asthma recurrence prevention during remission phases[2], secondary immune deficiency states including those seen with chronic diseases like Henoch-Schonlein purpura [3] or COPD exacerbations. Multiple randomized controlled trials have demonstrated its efficacy for symptom relief and reduction of recurrence rates across these indications with a favorable safety profile.

Brand names
Yupingfeng granulesYupingfeng powderYu-Ping-Feng-San
Other names
Yupingfeng SanYuPingFeng granulesYuPingFeng powder with variation
02

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CCL2 (C-C motif chemokine 2)IL8 (C-X-C Motif Chemokine Ligand 8)EGFR (Epidermal growth factor receptor)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)MMP9 (Matrix metalloproteinase-9)RELA (Nuclear Factor Kappa B Subunit p65)

Beyond the preview

Go deeper on yupingfeng.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on yupingfeng.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call